Tesamorelin: What the Research Looks At
Updated 2026-09-03
An education-first look at tesamorelin: what it is, its one approved use, and how compounded versions differ. Not medical advice.
What it is
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog, a class of peptide designed to stimulate the pituitary gland to release its own growth hormone rather than supplying growth hormone directly. A tesamorelin product marketed under the brand name Egrifta has been approved by the FDA for one narrow indication: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. This is an unusual position among the peptides covered on this site, since it means tesamorelin has real, approved human trial data behind it for that specific use, while compounded tesamorelin sold for general fitness, recovery, or anti-aging purposes is a separate, unapproved product with a much thinner evidence base.
How it is studied
The tesamorelin research supporting the Egrifta approval included controlled human clinical trials specifically in patients with HIV-associated lipodystrophy, evaluating changes in visceral fat over defined study periods. Outside that population, tesamorelin and other GHRH analogs have been studied in smaller trials and animal models exploring their effect on growth hormone and insulin-like growth factor 1 (IGF-1) levels, but this broader body of research is considerably thinner than the trial program that supported the approved indication. A search of PubMed shows ongoing interest in GHRH analogs across several research groups, though researchers in this space consistently note that extrapolating findings from the approved-indication population to a general healthy adult population is not established. Growth hormone and IGF-1 measurements are often used as laboratory markers in this research, but a change in a laboratory marker is a different thing from a demonstrated clinical benefit, and researchers are careful to keep those two ideas separate when reporting results.
What the research looks at
Beyond its approved use, researchers have examined GHRH analogs like tesamorelin in connection with body composition, sleep architecture, and age-related changes in growth hormone secretion. These are described as areas of ongoing investigation rather than settled outcomes, and the population studied matters: findings in patients with a defined medical condition do not automatically apply to a healthy adult using a compounded version for a different purpose. Researchers who study GHRH analogs generally call for more controlled trials outside the approved-indication population before broader conclusions can be drawn.
Regulatory status
Tesamorelin's regulatory picture has two separate tracks. As Egrifta, it is a
brand-name product approved by the FDA for HIV-associated lipodystrophy, manufactured and
labeled under standard pharmaceutical oversight. As a compounded substance sold outside
that specific product and indication, tesamorelin sits under the general 503A and 503B
compounding framework that applies to other research peptides, and its compounding status
has been subject to periodic FDA review (see
/regulation/fda-category-2-list-explained/ and
/regulation/503a-vs-503b-compounding-explained/). Readers researching a compounded,
non-Egrifta version should check the current
/regulation/fda-compounding-rulings-2026-update/ page rather than assume the approved
product's status extends to it.
Safety signals reported
Egrifta's approved labeling discloses a set of reported side effects from its clinical trial program, including injection-site reactions and effects on blood sugar regulation, information available through the FDA's Drugs@FDA database. Safety data for compounded tesamorelin used outside the approved indication is far less well characterized, since it was not the subject of the same controlled trial program. Growth hormone-pathway peptides in general carry theoretical concerns around insulin sensitivity and fluid retention that a clinician is positioned to evaluate for an individual's specific health profile. This is not medical advice. Discuss any decision about tesamorelin, approved or compounded, with a licensed healthcare provider first.
Questions to ask a clinician
- Does my situation match the specific indication tesamorelin's approval covers?
- If a compounded version is being discussed, what published evidence exists for that specific use?
- What effect could this have on my blood sugar or insulin sensitivity given my health history?
- What monitoring or lab work would you recommend before and during any use?
- How would you distinguish an approved product from a compounded version when evaluating a proposed treatment?
FAQ
Is tesamorelin approved by the FDA? A tesamorelin product marketed as Egrifta has been approved by the FDA for one specific indication: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That approval does not extend to compounded tesamorelin sold for general fitness or anti-aging purposes.
What is tesamorelin's mechanism? Tesamorelin is a growth hormone-releasing hormone (GHRH) analog, meaning it is designed to stimulate the body's own pituitary gland to release growth hormone, rather than supplying growth hormone directly.
Is compounded tesamorelin the same as Egrifta? No. Egrifta is a specific, approved formulation manufactured under FDA oversight for one indication. Compounded tesamorelin sold for other purposes is prepared by a pharmacy, is not the approved product, and is not backed by the same clinical trial data for those other purposes.
Is tesamorelin used in bodybuilding or anti-aging communities? Yes, tesamorelin is discussed in those communities as a growth hormone secretagogue, largely outside its one approved indication. That off-label, non-clinical use is not supported by the same evidence base as its approved use and carries its own separate regulatory and safety considerations.
Sources
- FDA, Drugs@FDA database search tool -- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B -- https://www.fda.gov/drugs/human-drug-compounding/fda-issues-list-bulk-drug-substances-outsourcing-facilities-may-use-compound-under-section-503b
- PubMed, search results for "tesamorelin growth hormone" -- https://pubmed.ncbi.nlm.nih.gov/?term=tesamorelin+growth+hormone
Disclaimer
This content is for general education only and is not medical advice, diagnosis, or treatment. Peptide Briefs does not sell peptides and does not recommend any specific product, dose, or protocol. These statements have not been evaluated by the Food and Drug Administration. Always talk with a licensed healthcare provider before starting, stopping, or changing any therapy.